Organon & Co. Common Stock vs Phillips 66 — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Phillips 66 trades at $298.75 (market cap $116.81B). The key difference: Phillips 66 is far larger — about 32.3× Organon & Co. Common Stock's market cap, and Phillips 66 pays the higher dividend (1.74%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Phillips 66 for 63 Days on average.
| OGN | PSX | |
|---|---|---|
Market Cap | $3.62B | $116.81B |
Volume | 2,892,999 | 2,609,145 |
Sector | Health | Energy |
52-Week High | $13.81 | $297.29 |
52-Week Low | $5.70 | $127.75 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $11.04B | $133.27B |
Dividend Yield | 0.58% | 1.74% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Phillips 66 (PSX) trades at $297.29, up 5.62% on the day, showing strong momentum near recent highs. The stock demonstrates solid fundamentals with a P/E of 16.71 and P/S of 0.78, while recent earnings beats and a 24.02% ROE highlight operational strength. Technical indicators show bullish momentum with the current price above key support levels. Recent news highlights structural advantages in refining margins and AI implementation for operational efficiency.
PSX presents a compelling investment case with strong profitability metrics and positive analyst sentiment (54% buy ratings), though current price exceeds the $286.90 consensus target. Key risks include refining margin volatility and potential policy impacts on diesel exports. The company's debt reduction progress and projected 2026 net cash flow of $3.0B support the bullish outlook despite competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →